Cumberland cuts sales staff to 64 from 95 employees Cumberland Pharmaceuticals implemented a realignment of its national sales organization in the United States. As a result of this realignment on November 29, the company’s sales personnel moved from 95 individuals to 64 individuals and consolidated its number of nationwide districts from 10 to 8. The company does not expect to have further changes to its sales personnel as a result of the realignment. The impact on the company’s earnings will be addressed in its 2013 guidance. The company expects to incur and pay between $500,00 and $750,000 in one-time separation expenses related to this realignment during Q4 ending Dec 31.
Cumberland announces approval of Caldolor injection Cumberland announced the approval of Caldolor Injection for pediatric patients six months of age and older. The approval was based on data submitted to the U.S. Food and Drug Administration (FDA) as part of a post-marketing commitment following approval of Caldolor in adults in 2009. Caldolor is the first and only injectable non-steroidal anti-inflammatory drug approved for use in pediatric patients.